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Abstract: 
 
Purpose: The purpose of this review was to summarize the literature on the relationship between 
obesity and survival in persons with heart failure (HF). In particular, the article examines the 
ways in which studies define body size/composition (body mass index [BMI], body composition, 
weight, cachexia, fluid retention, or albumin) and the relationship of BMI and survival after 
controlling for factors such as HF severity, etiology of the HF, gender, race, age, and/or time 
since HF diagnosis. 
 
Data sources: The keywords heart failure and body mass index, heart failure and obesity, and 
heart failure and body composition were indexed in PubMed. Articles published from 1999 to 
2006 that used multivariate analyses to examine the relationship between obesity and survival in 
persons with HF were included in the review. 
 
Conclusions: BMI is the standard most often used for measuring body weight in patients with 
HF. Yet, BMI does not address other major components of body weight (fat, lean body mass, and 
fluid) that may factor into the mortality of patients with HF. Four of the six studies reviewed 
reported a positive relationship between obesity and improved survival. However, the studies are 
limited by design, with the majority being cross-sectional. Furthermore, most of the data were 
collected through secondary data analysis from patient records in the 1990s, before 
contemporary HF treatment was used. 
 
Implications for practice: Until further research solidifies a clear association between higher 
BMIs and improved survival in patients with HF, nurse practitioners and others should continue 
to counsel their patients with HF who are overweight to lose weight. Assessing BMI alone as a 
predictor of survival for patients with HF may be misleading and should be performed in the 
context of other factors. Moreover, care should be taken in managing patients with HF who are 
cachexic because these patients have a worrisome prognosis. 
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Article: 
 
Introduction 
 
The prevalence of heart failure (HF) in the United States is expected to increase from 5.2 million 
in 2004 (Rosamond et al., 2007) to 10 million by 2030 (Adams et al., 1999). This rise in HF has 
been attributed to the advancing age of the population; rising obesity; and the added stress of 
hypertension (HTN), smoking, obesity, high-fat/high-cholesterol diet, sedentary lifestyle, and 
diabetes mellitus (DM), all of which either cause myocardial damage or increase myocardial 
workload (Hall et al., 2005). Despite recent advances in the management of patients with HF, 
morbidity and mortality rates remain high, with an estimated 5-year mortality rate of 50% 
(Zevitz, 2005). In fact, HF is the only cardiovascular condition in which there has not been a 
substantial decline in both incidence and prevalence over the past 20 years (taking into account 
the progressive aging of the population) (Stewart, MacIntyre, Capewell, & McMurray, 2003). 
Thus, HF poses a great burden on the population and the healthcare system. 
 
Nearly, a third of Americans are obese (Murphy et al., 2005). Obesity is a risk factor for HF and 
many other diseases, increasing the chance of developing other significant cardiovascular risk 
factors such as HTN, DM, and dyslipidemia. The Framingham Heart Study found that being 
overweight or obese was an independent predictor of HF (Kenchaiah et al., 2002). In fact, 
overweight women have a 50% greater risk of developing HF. Further, in patients with 
established HF, obesity has been found to be associated with an increased risk of mortality 
(Eckel, 1997) and is consistently associated with left ventricular hypertrophy and dilatation 
(Kenchaiah et al.). This prior evidence had led clinicians toward recommendations for weight 
loss for the obese in both the general population and those with HF (Adams et al., 2006). 
However, more recent research suggests that obesity may actually be associated with improved 
survival in persons already diagnosed with HF (Curtis et al., 2005; Davos et al., 2003; 
Gustafsson et al., 2005; Hall et al., 2005; Horwich et al., 2001; Lavie, Osman, Milani, & Mehra, 
2003). This research suggests that clinicians may need to distinguish between weight 
management strategies for healthy individuals as opposed to those with HF (Curtis et al.). 
 
This article reviews the current evidence regarding whether obesity is indeed protective in 
persons with HF. Specifically, the article examines the ways in which studies define body 
size/composition (by body mass index [BMI], body composition, weight, cachexia, fluid 
retention, or albumin) and the relationship of BMI and survival after controlling for factors such 
as (a) severity of HF (left ventricular ejection fraction [LVEF] and/or New York Heart 
Association [NYHA] functional class; Table 1), (b) etiology of HF (ischemic vs. nonischemic), 
(c) age, (d) gender, (e) race, and (f) time since HF diagnosis. 
 
Table 1.  Criteria for NYHA functional classification in patients with HF 
NYHA class Definition 
NYHA class I No limitation in physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitations, or dyspnea. 
NYHA class II Slight limitation of physical activity. Comfortable at rest, but 
ordinary physical activity results in fatigue, palpitations, or 
dyspnea. 
NYHA class III Marked limitation of physical activity. Comfortable at rest, but 
less than ordinary activity causes fatigue, palpitations, or dyspnea. 
NYHA class IV Unable to carry on any physical activity without discomfort. 
Symptoms of cardiac insufficiency present at rest. If any physical 
activity is undertaken, discomfort is increased. 
Note. Adapted from HFSA 2006 comprehensive heart failure practice guideline (HFSA 2006). 
 
Method 
 
The keywords heart failure and body mass index, heart failure and obesity, and heart failure and 
body composition were indexed in PubMed. All published articles from 1999 to 2006 that 
examined a relationship between obesity and survival in persons with HF were examined. The 
abstracts of original articles reporting studies of HF, obesity, and the relationship of BMI to body 
composition were reviewed. Articles were included in the review if the study used multivariate 
analyses to examine the relationship between obesity and HF survival. 
 
Review of the evidence: Link of BMI to survival 
 
Six studies published between the years 1999 and 2006 met the criteria for the analysis 
(Table 2). Horwich et al. (2001) were the first to report the possible beneficial effects of obesity 
on the survival of patients with HF. They analyzed hospital records from 1203 patients with 
advanced systolic HF (NYHA classes III and IV = 93.9%) who were referred to a university 
medical clinic for heart transplant evaluation and were followed in a comprehensive HF 
management program. BMI was used as the primary index of obesity, with percent ideal body 
weight (PIBW) used as an alternative index of total body fat. To rule out edema as a confounder 
for accuracy of body size/composition, weights were measured upon conclusion of pulmonary 
artery catheter-guided therapy. This assured that the optimal hemodynamics and euvolemia had 
been achieved (Horwich et al.). The researchers expected that obese patients with HF would have 
worse mortality outcomes than those with recommended weight (20.7–27.7 kg/m2 for the 
purposes of this study). On univariate analysis, however, low LVEF, low peak VO2 (oxygen 
consumption), high pulmonary capillary wedge pressure, and low use of angiotensin-converting 
enzyme (ACE) inhibitors were predictors of mortality at 1 year. However, higher BMI and 
PIBW were not predictors of mortality. Furthermore, multivariate analysis determined that a 
higher BMI level was not associated with improved survival at 12 months (p = .072). Although a 
higher BMI was associated with a survival benefit at 2 years (p = .016), the benefit was not 
sustained at 5 years (p = .259). When PIBW was used as an alternative to BMI, the same 
relationships held true (Horwich et al.). 
 
Table 2.  Selected results from studies reviewed 
Study, 
sample 
size, and 
year of 
data 
collection 
Overall result NYHA class =n(%) 
Severity of 
HF (LVEF) 
Etiology of 
HF Age (years) Gender Race 
Horwich et 
al. (2001), 
1203 
subjects, 
and 
between 
1983 and 
1999 
BMI and PIBW 
were not 
predictors of 
survival at 1 year 
(p = .07) and 5 
years (p= .259); 
BMI and PIBW 
were predictors of 
survival at 2 years 
(p = .016) 
NYHA II = 
66 (5.5); 
NYHA III = 
401 (33.3); 
NYHA IV = 
729 (60.6) 
Mean LVEF 
= 22%; LVEF 
> 40% were 
excluded 
Ischemic = 
48% 
Average age 
for each 
category of 
BMI: 
underweight 
= 48.4 ± 15.4; 
normal 
weight = 53.2 
± 11.4; 
overweight = 
52.5 ±10.0; 
and obese = 
48.5 ± 11.5 
Males = 
76.6% 
Not 
reported 
Lavie et al. 
(2003), 
209 
subjects, 
and 
between 
1996 and 
1998 
Higher percent 
body fat and BMI 
were independent 
predictors of 
event-free 
survival; events 
included 
cardiovascular 
death (13) or 
urgent 
transplantation 
(15) 
NYHA I = 21 
(10.1); 
NYHA II = 
86 (41.1); 
NYHA III = 
102 (48.8) 
LVEF = 19% 
for event 
group; LVEF 
= 24% ± 13 
for event-free 
group 
Ischemic = 
42% 
Major clinical 
events—with 
events: age = 
53 ± 13; 
event-free 
group: age = 
54 ± 12 
Male = 81% Not 
reported 
Davos et 
al. (2003), 
525 
subjects, 
and 
between 
1991 and 
2000 
Improved 
survival in 
noncachectic 
group; in the 
noncachectic 
group, quintile 4 
(mean BMI: 29.2 
kg/m2) had the 
best 12- and 36-
month survival 
Noncachectic 
patients: 
NYHA I = 
101 (19.2); 
NYHA II = 
230 (43.8); 
NYHA III = 
152 (28.95); 
NYHA IV = 
42 (8) 
Noncachectic 
patients: 
LVEF = 31.6 
± 14.8 
Noncachectic 
patients: 
ischemic = 
57% 
Noncachectic 
patients: 
average age = 
61.0 ± 12.4 
Noncachectic 
patients: male 
= 83% 
Not 
reported 
Study, 
sample 
size, and 
year of 
data 
collection 
Overall result NYHA class =n(%) 
Severity of 
HF (LVEF) 
Etiology of 
HF Age (years) Gender Race 
Curtis et 
al. (2005), 
7767 
subjects, 
and 
between 
1991 and 
1993 
Improved 
survival in 
overweight and 
obese group; 
possible plateau 
effect, with BMI 
> 35 kg/m2 
NYHA I = 
1087 (14); 
NYHA II = 
4272 (55); 
NYHA III/IV 
= 2408 (31) 
LVEF = 31.9 
± 12.5 
Ischemic = 
68.9% 
Age = 63.9 ± 
10.9 
Male = 75.4% African 
American 
= 14.4% 
Hall et al. 
(2005), 
2707 
subjects, 
and from 
1995 to 
unknown 
Improved 
survival with 
higher BMI 
groups 
Not reported LVEF ≤ 40% Not reported Not reported Not reported Not 
reported 
Gustafsson 
et al. 
(2005), 
4700 
subjects, 
and 
between 
1993 and 
2002 
Improved 
survival with 
higher BMI 
groups—only in 
those with 
preserved LVEF 
and without 
COPD 
NYHA III 
and IV only 
LVEF ≤ 0.35 Ischemic = 
58% 
Age = 72.4 Male = 61%; 
more males in 
the 
overweight 
and obese 
groups 
Not 
reported 
 
Lavie et al. (2003), who retrospectively studied 209 ambulatory patients with mild-to-moderate 
HF (NYHA classes I–III), examined the impact of obesity and various body composition 
parameters on clinical outcomes in patients with chronic systolic HF. Five body composition 
parameters were assessed: body surface area, BMI, percent body fat, total fat, and lean body 
weight. Using established methods, body surface area was estimated from the patient’s height 
and body weight and reported in square meters. Percent body fat was determined using the 
average of three skinfold measures to estimate total body fat (body weight in kilogram multiplied 
by percent body fat) and lean body weight (body weight in kilogram minus total body fat). 
 
Patients with the lowest percentage of body surface area (2.0 m2), BMI (27.7 kg/m2), body fat 
(22.5%), total fat (19.7 kg), and lean body weight (65.5 kg) had the highest percentage of major 
clinical events (cardiovascular death and urgent transplantation). A higher percentage of body fat 
was the strongest independent predictor of event-free survival (p = .002). In fact, as percent body 
fat increased by 1%, the likelihood of clinical events decreased by more than 13%. When percent 
body fat was replaced by BMI and total fat, the relationships held true. Other independent 
predictors of event-free survival based on multivariate analysis were a nonischemic etiology and 
higher peak oxygen consumption. It is important to note that more than half (15) of the 28 major 
clinical events were urgent transplantation. Furthermore, the obese patients in this study were 
significantly younger than the lean patients (p < .02); yet, age, LVEF, NYHA class, and gender 
were not predictors of event-free survival in multivariate analysis. 
 
Cachexia has been recognized as a risk factor for mortality, leading Davos et al. (2003) to 
prospectively study 589 patients with chronic HF in order to determine whether BMI had a 
differential effect on survival in persons with and without cardiac cachexia. Cachexia was 
defined as a nonedematous and unintentional weight loss of more than 7.5% over the past 6 
months. The researchers hypothesized that because chronic HF appears to be an inherently 
catabolic state, a higher BMI might prove protective even in the absence of cachexia. 
 
To test this hypothesis, Davos et al. (2003) compared survival rates in patients with cachexia (n = 
64) to those without cachexia (n = 525). Patients with primary cachexic states (infection, 
malignant disorder, thyroid disorder, severe liver disease, or acquired immunodeficiency 
syndrome) were excluded from the study. Noncachexic patients were categorized into quintiles 
according to their BMI (quintile means and standard deviations were as follows—BMI at 
quintile 1: 22.2 kg/m2± 1.5; at quintile 2: 24.9 kg/m2± 0.6; at quintile 3: 26.9 kg/m2± 0.6; at 
quintile 4: 29.2 kg/m2± 0.8; and at quintile 5: 34.1 kg/m2± 2.8). 
 
Improved 12-month survival was found in the noncachexic group compared to the cachexic 
group (OR = 2.71 [95% confidence interval (CI): 1.94–3.79]; Davos et al., 2003). In other words, 
cachexic subjects were almost three times more likely to die than the noncachexic subjects. On 
average, the cachexic group was 4 years older and had a lower LVEF (by 5.3%), worse exercise 
capacity, and lower systolic blood pressure (by 14.9 mmHg), compared to the noncachexic 
group. 
 
In the noncachexic group, subjects who were moderately obese, those with BMI values in the 
fourth quintile (mean ± SD BMI: 29.2 kg/m2± 0.8), had the best survival at 1 year (p = .01) and 3 
years (p < .0001). When examining survival rates, the relative risk of death compared to the 
improved survival for the fourth quintile was 2.3 for quintile 1 (p = .001), 1.7 for quintile 2 (p = 
.027), 1.8 for quintile 3 (p = .016), and 1.5 for quintile 5 (p = .14). Multivariate analysis revealed 
that an increased BMI, a higher LVEF, and better exercise capacity (peak oxygen consumption) 
were independent predictors of survival, even after correcting for age, presence of ischemic heart 
disease (IHD) as an etiology, NYHA class, and duration of disease. It is important to note that 
short-term survival rates (first 2 years) and the lowest BMI quartile of noncachexic subjects were 
similar to those of cachexic subjects. Furthermore, authors considered the possibility of whether 
a U-shaped relationship existed between BMI and survival in HF, in which the very thin and the 
very obese had worse survival. However, the number of subjects in the extreme BMI categories 
did not permit for testing for a curvilinear relationship. 
 
Curtis et al. (2005) also reported improved survival in patients with an increased BMI. The 
authors retrospectively studied the association between BMI and outcomes in 7767 stable 
outpatients with HF between the years 1991 and 1993 using the Digitalis Investigation Group 
trial database. Subjects were grouped according to BMI into four categories as defined by The 
United States Preventive Services Task Force (2003). More than half the participants were 
overweight (BMI 25.0–29.9 kg/m2) or obese (BMI ≥ 30.0 kg/m2). A smaller proportion of 
overweight (32.4%) and obese (28.4%) patients died during follow-up than did underweight 
(45%) or normal weight (37.8%) patients. Thus, patients who were overweight or obese were 
less likely to die, with adjusted hazard ratios of 0.88 (95% CI: 0.80–0.96) and 0.81 (95% CI: 
0.72–0.92), respectively, compared to those with a normal BMI (18.5–24.9 kg/m2). Whereas, the 
risk of death for those underweight was greater than for those with a normal BMI, with an 
adjusted hazard ratio of 1.21 (95% CI: 0.95–1.53). Rates of all-cause hospitalization and 
hospitalization because of worsening HF were similar across BMI groups (underweight = 70.6%, 
normal weight = 64.7%, overweight = 65.6%, and obese = 67.2%). The relationship between 
BMI and HF outcomes (survival and hospitalization rates) held when subjects were stratified by 
LVEF, HF etiology, gender, and duration of HF. Authors, however, noted a possible plateau 
relationship between BMI and survival among the very obese patients (BMI > 35 kg/m2) as this 
subgroup had an increased risk of death. 
 
Hall et al. (2005) examined long-term survival (6 years) of hospitalized patients with HF based 
on BMI, controlling for age, gender, and severity of illness. In this retrospective review of 
patients in a 20-hospital integrated healthcare delivery system, all 2707 patients had a primary 
diagnosis of HF identified by ICD-9 coding or by identification of an LVEF ≤ 40%. BMI was 
used as the measure of body weight and was calculated using the first measured heights/weights 
at hospital admission. Quartiles for this study were defined as follows—BMI at quartile 1: <24.3 
kg/m2, at quartile 2: 24.4–28.5 kg/m2, at quartile 3: 28.6–34.1 kg/m2, and at quartile 4: ≥34.2 
kg/m2. Three-year survival rates improved with increasing BMI quartiles (quartile 1 = 57%, 
quartile 2 = 61%, quartile 3 = 69%, and quartile 4 = 74%). After adjusting for age, gender, and 
severity of HF (not defined), survival rates were better for the three highest BMI quartiles, with 
adjusted hazard ratios of 0.77 (95% CI: 0.63–0.94) for quartile 1, 0.70 (95% CI: 0.56–0.86) for 
quartile 2, and 0.77 (95% CI: 0.59–0.99) for quartile 3, compared to those in quartile 1, with a 
BMI < 24.3 kg/m2. 
 
Like Hall et al. (2005), Gustafsson et al. (2005) evaluated the influence of BMI and LVEF on 
mortality in subjects hospitalized with HF. They examined a total of 4700 subjects with new or 
worsening HF from the Danish Investigations of Arrhythmia and Mortality on Dofetilide HF 
registry. Patients were categorized into four groups based on their BMI (underweight: <18.5 
kg/m2, normal weight: 18.5–24.9 kg/m2, overweight: 25–30 kg/m2, and obese: >30 kg/m2). These 
subgroups are very similar to those used by Curtis et al. (2005), as recommended by The United 
States Preventive Services Task Force (2003). 
 
As in the previous studies, the risk of death decreased steadily with increasing BMI from the 
underweight to the obese. At the end of follow-up (ranging from 5 to 8 years), after adjusting for 
age and gender, the risk ratios (RRs) for death were 1.56 (95% CI: 1.33–1.84) for those 
underweight, 0.90 (95% CI: 0.83–0.97) for those overweight, and 0.77 (95% CI: 0.70–0.86) for 
the obese group. However, when a subgroup analysis was performed, the overweight or obese 
subjects with a decreased LVEF had an excessive risk of mortality. In fact, for those with 
systolic dysfunction, the obese subjects had an RR of 1.21 (95% CI: 1.01–1.45) compared to 
those subjects of normal weight. In other words, of the overweight and the obese, only those with 
preserved left ventricular function (normal or high LVEF) had improved survival. Furthermore, 
the authors also found that the effect of BMI on survival depended on the presence or absence of 
coexisting chronic obstructive pulmonary disease (COPD). Thus, this study hints that the 
protective effect of higher BMI status on HF survival is dependent on the presence of preserved 
systolic function and the absence of coexisting COPD (Gustafsson et al., 2005). 
 
Discussion 
 
Four studies included in this analysis found a significant positive association between obesity 
and HF survival; however, two of the four studies suggested that a nonlinear relationship may 
exist. Four of the six studies used body weight and height recorded during initial screening, and 
then categorized participants into BMI groups. Lavie et al. (2003) used body composition 
parameters (body surface area, percent body fat, total fat, and lean body weight) in addition to 
BMI. Horwich et al. (2001) used both BMI and PIBW while making sure that subjects were 
euvolemic prior to using those numbers for analysis. All studies divided their sample into BMI 
quartiles or quintiles that were roughly similar, allowing for comparison across studies. 
However, cross-comparison is challenging because ranges of data were not reported in all studies 
(only mean values). 
 
Most of the studies used BMI measured at one point in time as the sole determinant of body 
composition. While BMI is a simple, commonly used measure for rating obesity level, it is 
misleading, given that BMI ignores the major components of body weight: fat, lean body mass, 
and fluid (Heyward & Wagner, 2004). Specifically, BMI does not take into account differences 
in the proportion of fat to lean body mass or the distribution of fat, a factor that previous research 
suggests is important for predicting HF survival (Heyward & Wagner). Furthermore, BMI 
overestimates body fat in people who are very muscular or who have edema. For example, it 
overestimates fat in young adult males compared to young adult females because of the lesser 
percent body fat in males. BMI also seems to be overestimated in Caucasians, when age- and 
gender- matched with other ethnic groups (Heyward & Wagner). Conversely, BMI 
underestimates body fat in people who have lost muscle mass, such as the elderly (Brigham and 
Women’s Hospital, 2003). BMI also has limitations for individuals or populations with extremes 
of heights or who have very long or short limb lengths in relation to trunk measurement (World 
Health Organization, 1995). 
 
Davos et al. (2003) provided the best insight into the problem because the authors specifically 
classified subjects in terms of cachexic states. In HF, the wasting process affects not only muscle 
but also fat, bone, and the heart (Anker et al., 2003). Lean body mass is usually within normal 
limits at the time of diagnosis, unless the patient has an underlying morbidity that causes muscle 
or protein loss. Depletion of lean body mass contributes to complications and exacerbations of 
HF. As cardiac cachexia develops near the time of death, lean body mass is nearly depleted 
(Poirier et al., 2006). In the study by Davos, survival of patients in the lowest BMI quintile was 
similar to that of cachexic patients for the first 2 years of follow-up, but long-term survival did 
not differ between any of the groups (Davos et al.). Thus, further studies are needed to examine 
changes in BMI over time and evaluate the effects of cardiac cachexia. 
 
It is also possible that patients’ BMI reflects changes in other prognostic indicators. For example, 
patients with sarcopenia or decreased muscle mass are known to have restricted exercise capacity 
and reduced mobility, both of which are associated with increased mortality (Roubenoff, 2000). 
Moreover, an increase in BMI, even in the obese, may not be related to elevations in body fat but 
may reflect preserved or increased lean mass. In order to assess regional adiposity and fat 
distribution, anthropometric measurements should be used, including waist circumference or 
sagittal abdominal diameter (Heyward & Wagner, 2004). Clearly, further research on the topic of 
HF and body weight should include other measurements of the distribution of body weight. 
 
Perhaps, the greatest limitation of the research to date when examining the relationship between 
obesity and HF survival is identifying potential variables that demonstrate an interaction between 
body size/composition and survival. In the studies reviewed, six variables (severity of HF, 
etiology of HF, gender, race, age, and time since HF diagnosis) were examined to determine if 
relationships existed between BMI and survival for persons with HF. 
 
Patients with systolic dysfunction (associated with a lower LVEF) have a higher mortality rate 
(10%–15% annually) than those with diastolic HF (associated with preserved LV function, 5%–
8% annually; Franklin & Aurigemma, 2005). However, for patients with HF older than 70 years, 
mortality rates for diastolic HF approach those for systolic HF. For patients with systolic HF, 
mortality rates are directly related to age and the presence of an ischemic etiology (Franklin & 
Aurigemma). In the six studies reviewed, all considered LVEF as a variable in their models for 
analysis. 
 
Croft et al. (1999) found that patients with IHD as an etiology of HF had less favorable 6-year 
survival than those with HTN or combined HTN and IHD. IHD was the most common comorbid 
condition among white patients with HF, whereas HTN was the most common comorbid 
condition among black patients. It is possible that increased use of ACE inhibitors and blockers 
following myocardial infarction or as part of HTN management has reduced disease severity 
among HF patients with these conditions (Croft et al.). 
 
Mortality as a result of HF has been shown to rise in parallel with age. The incidence of HF 
increases dramatically with age in both sexes, approximately doubling with each advancing 
decade (Kenchaiah et al., 2002). Comorbid conditions also influence survival. Gustafsson et al. 
(2005) found that the effect of BMI on mortality in HF appeared to depend on whether COPD 
and other diseases like renal insufficiency, stroke, and diabetes were present. 
 
Gender and race have also been shown to be prognostic indicators for survival of patients with 
HF. Women with HF lived longer than men, with a median survival after the diagnosis of HF of 
3.2 vs. 1.7 years (Kannel, Ho, & Thom, 1995). Black patients with HF had lower mortality than 
white patients during follow-up and slightly higher survival during each year of follow-up. Six-
year survival was 19% among black men, 16% among white men, 25% among black women, 
and 23% among white women. After taking into account differences in age, white men had 10% 
greater mortality than black men (age-adjusted RR: 1.10 [95% CI: 1.07–1.13]; Croftet al., 1999). 
Yet, as shown in Table 2, the majority of the studies examined in our review did not report race 
and thus did not factor race into multivariate analyses. Additionally, males were overrepresented 
in the five studies that reported descriptive statistics for gender. 
 
 
Conclusions 
 
HF is the only cardiovascular condition not experiencing a substantial decline in both incidence 
and prevalence over the past 20 years (Stewart, MacIntyre, Capewell, & McMurray, 2003). 
Accordingly, continued research focusing on prevention and management of HF is needed. This 
review of the literature suggests an association between obesity and improved survival in 
patients with HF. However, until a mechanism is identified to explain this obesity paradox, 
causality cannot be satisfactorily explained. Given the limitations of using BMI alone, there need 
to be other ways to understand the relationship between weight and mortality as a result of HF. 
Further research is necessary to prospectively study within the context of contemporary HF 
treatment the prognostic implications of BMI and aspects of body composition, taking into 
consideration other complex factors such as natriuretic peptides, plasma norepinephrine, 
nutritional status, and caloric intake that relate to HF survival. With such studies, definitive 
weight loss recommendations for patients with HF will be forthcoming. 
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